2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148083
    TBBPA-sulfate 902525-22-8 98%
    TBBPA-sulfate is metabolite of TBBPA. TBBPA has been reported to enhance adipogenesis by binding with the peroxisome proliferator-activated receptor gamma (PPARγ).
    TBBPA-sulfate
  • HY-148223
    Tolindate 27877-51-6 98%
    Tolindate is a potent PXR agonist with an EC50 value of 8.3 μM. Tolindate shows antifungal activity.
    Tolindate
  • HY-14823R
    Sobetirome (Standard) 211110-63-3 98%
    Sobetirome (Standard) is the analytical standard of Sobetirome. This product is intended for research and analytical applications. Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.
    Sobetirome (Standard)
  • HY-148285
    Succinyl CoA 604-98-8 98%
    Succinyl CoA (Succinyl-coenzyme A) is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis).
    Succinyl CoA
  • HY-14829A
    Afegostat hydrochloride 161302-93-8 98%
    Afegostat hydrochloride (D-Isofagomine hydrochloride) is a potent β-galactosidase inhibitor with activity ameliorating GM1-gangliosidosis and Morquio B disease-associated mutations. Afegostat hydrochloride is able to induce the maturation of mutant β-galactosidase in fibroblasts from patients with GM1-gangliosidosis. Afegostat hydrochloride also promotes the reduction of keratin sulfate and oligosaccharide load in patient cells.
    Afegostat hydrochloride
  • HY-14831A
    (+)-Arhalofenate 1030594-28-5 99.85%
    (+)-Arhalofenate ((+)-MBX 102) is the less active enantiomer of Arhalofenate (HY-14831). Arhalofenate is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
    (+)-Arhalofenate
  • HY-148563
    GPR81 agonist 2 1143024-28-5 98%
    GPR81 agonist 2 (compound 1) is a potent GPR81 agonist with EC50 values of 0.023, 0.123 µM for hGPR81, hGPR109A, respectively.
    GPR81 agonist 2
  • HY-14874R
    Topiroxostat (Standard) 577778-58-6 98%
    Topiroxostat (Standard) is the analytical standard of Topiroxostat. This product is intended for research and analytical applications. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.
    Topiroxostat (Standard)
  • HY-14877R
    Anagliptin (Standard) 739366-20-2 98%
    Anagliptin (Standard) is the analytical standard of Anagliptin. This product is intended for research and analytical applications. Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively.
    Anagliptin (Standard)
  • HY-14894R
    Ipragliflozin (Standard) 761423-87-4 98%
    Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.
    Ipragliflozin (Standard)
  • HY-148977
    18:0,22:6 PS sodium 474943-18-5 98%
    18:0,22:6 PS sodium is a lipid component of synaptic vesicles and cholesterol, which can be used for metabolic research.
    18:0,22:6 PS sodium
  • HY-14914R
    Azilsartan (Standard) 147403-03-0 98%
    Azilsartan (Standard) is the analytical standard of Azilsartan. This product is intended for research and analytical applications. Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research.
    Azilsartan (Standard)
  • HY-149605
    KHK-IN-4 3034829-40-5 98%
    KHK-IN-4 (compound 14) is a potent ketohexokinase (KHK) inhibitor. KHK-IN-4 can be used for fructose metabolic disease research.
    KHK-IN-4
  • HY-149657
    SREBP/SCAP-IN-1 2763493-89-4 98%
    SREBP/SCAP-IN-1(compound 10b) is a selectiveSREBP/SCAPinhibitor.
    SREBP/SCAP-IN-1
  • HY-149658
    SREBP/SCAP-IN-2 2763493-94-1 98%
    SREBP/SCAP-IN-2(compound 13) is a selectiveSREBP/SCAPinhibitor.
    SREBP/SCAP-IN-2
  • HY-149711
    Farnesylcysteine 68000-92-0 99.29%
    Farnesylcysteine (FC) is a competitive inhibitor of ICMT. The fcly mutant has quantitatively low farnesylcysteine (FC) lyase activity and an enhanced response to ABA. Farnesylcysteine induces an ABA hypersensitive phenotype in Arabidopsis thaliana.
    Farnesylcysteine
  • HY-149807
    TGR5 agonist 1 3027426-02-1 98%
    TGR5 agonist 1 (compound 18) is a potent TGR5 agonist with an EC50 value of 0.31 µM.
    TGR5 agonist 1
  • HY-15145R
    SRT 1720 monohydrochloride (Standard) 2060259-60-9 98%
    SRT 1720 (monohydrochloride) (Standard) is the analytical standard of SRT 1720 (monohydrochloride). This product is intended for research and analytical applications. SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3.
    SRT 1720 monohydrochloride (Standard)
  • HY-15291R
    MBX-2982 (Standard) 1037792-44-1 98%
    MBX-2982 (Standard) is the analytical standard of MBX-2982. This product is intended for research and analytical applications. MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (GPR119) agonist.
    MBX-2982 (Standard)
  • HY-152940
    βGlcCer 887907-50-8 98%
    βGlcCer is a glycosphingolipid. βGlcCer directly increases the development and PKCα and PKCδ activation in mouse bone marrow-derived DCs (BMDCs). β-GlcCer accumulating in Gaucher disease activates microglia through macrophage-inducible C-type lectin (Mincle) to induce phagocytosis of living neurons, which exacerbates Gaucher symptoms.
    βGlcCer
Cat. No. Product Name / Synonyms Application Reactivity